Abbott has secured CE Mark for what it's calling the world's first dual glucose‑ketone sensing technology for people with diabetes.
Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, providing visibility into both glucose levels needed for daily diabetes management as well as rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency.
Abbott plans to begin launching Libre Duo systems in select European countries later this year.
Libre Duo systems continuously monitor both glucose and ketone levels, reducing reliance on blood or urine tests that capture only a single moment in time. The sensors are designed to help people with diabetes monitor glucose levels – the standard of care for daily diabetes management – while also alerting people to rising ketones so they can act sooner and potentially avoid a serious DKA emergency.
This CE Mark covers two Libre Duo systems. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Clinical data indicate that a 10-day sensor can help active youth complete the full wear period. Both sensors deliver consistent, strong accuracy.
Libre Duo systems will integrate with Abbott's Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors.
Libre Duo systems are not yet cleared or available for sale in the United States.
